Abstract
Addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage HER2-positive breast cancer. Still, up to 50% of patients have residual disease following treatment, while others are likely overtreated. Here, we performed multiplex spatial proteomic characterization of 122 samples from 57 HER2-positive breast tumors from the neoadjuvant TRIO-US B07 clinical trial sampled pre-treatment, after 14-21 days of HER2-targeted therapy, and at surgery. We demonstrate that proteomic changes following a single cycle of HER2-targeted therapy aids the identification of tumors that ultimately undergo pCR, outperforming pre-treatment measures or transcriptomic changes. We further developed and validated a classifier that robustly predicts pCR using a single marker, CD45, measured on-treatment, and show that CD45-positive cell counts measured via conventional immunohistochemistry perform comparably. These results demonstrate novel biomarkers to enable the stratification of sensitive tumors early during neoadjuvant HER2-targeted therapy with implications for tailoring subsequent therapy.
Competing Interest Statement
SAH received contracted research and medical writing assistance from Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana. MK, ZZ, MH, JB are all employees of NanoString Inc. and declare that there are competing interests. DJS received research funding from Pfizer, Novartis, Syndax, Millenium Pharmaceuticals, Aileron Therapeutics, Bayer, and Genentech, owned stock in Biomarin, Amgen, Seattle Genetics, and Pfizer, served on the Board of Directors for BioMarin, and performed consulting/advisory board work for Eli Lilly, Novartis, Bayer, and Pfizer. CC is a scientific advisor to GRAIL and reports stock options as well as consulting for GRAIL and Genentech. KLM, JLC, ZM, RJ, EK, GB, JZ have no conflicts of interest to report.
Funding Statement
This project was supported by awards from the National Institutes of Health/National Cancer Institute (R01CA182514) and the Breast Cancer Research Foundation to C.C. C.C. is also a Susan G. Komen Scholar. KLM is supported by F30CA239313-02 from the NIH/NCI. JLC is supported by a Damon Runyon Physician-Scientist Training Award and a Susan G. Komen Postdoctoral Fellowship Award (PDR17481769).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB at the University of California Los Angeles (UCLA) approved the clinical trial TRIO-US B07 (08-10-035). The IRB at Stanford approved the use of the TRIO-US B07 clinical trial specimens for correlative studies in the Curtis Lab (eProtocol #32180). Informed consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability Data associated with the manuscript to be available online.
